Malta - English - Medicines Authority

pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 500 mg - all other therapeutic products

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gabapentin, quantity: 300 mg - capsule, hard - excipient ingredients: maize starch; lactose; purified talc; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate - pharmagabapentin is indicated for the treatment of,? partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,? neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gabapentin, quantity: 400 mg - capsule, hard - excipient ingredients: maize starch; lactose; purified talc; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate - pharmagabapentin is indicated for the treatment of,? partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,? neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gabapentin, quantity: 100 mg - capsule, hard - excipient ingredients: lactose; purified talc; maize starch; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - pharmagabapentin is indicated for the treatment of,? partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,? neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - piperacillin sodium, quantity: 4170 mg (equivalent: piperacillin, qty 4000 mg); tazobactam sodium, quantity: 536 mg (equivalent: tazobactam, qty 500 mg) - injection, powder for - excipient ingredients: - omegapharm piperacillin and tazobactam is indicated for the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the following conditions, - lower respiratory tract infections, - urinary tract infections (complicated and uncomplicated), - intra-abdominal infections, - skin and skin structure infections, - bacterial septicaemia, and, - gynaecological infections. children under the age of 12 years. in hospitalised children aged 2 to 12 years, omegapharm piperacillin and tazobactam is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years. . while omegapharm piperacillin and tazobactam is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing, piperacillin resistant organisms. appropriate culture and susceptibility tests sho

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - piperacillin sodium, quantity: 2085 mg (equivalent: piperacillin, qty 2000 mg); tazobactam sodium, quantity: 268 mg (equivalent: tazobactam, qty 250 mg) - injection, powder for - excipient ingredients: - omegapharm piperacillin and tazobactam is indicated for the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the following conditions, - lower respiratory tract infections, - urinary tract infections (complicated and uncomplicated), - intra-abdominal infections, - skin and skin structure infections, - bacterial septicaemia, and, - gynaecological infections. children under the age of 12 years. in hospitalised children aged 2 to 12 years, omegapharm piperacillin and tazobactam is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years. . while omegapharm piperacillin and tazobactam is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing, piperacillin resistant organisms. appropriate culture and susceptibility tests sho

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - ceftazidime pentahydrate, quantity: 2349 mg (equivalent: ceftazidime, qty 2000 mg) - injection, powder for - excipient ingredients: sodium carbonate - omegapharm ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. . indications include the following.. severe infections in general. for example: septicaemia (including neonatal sepsis), bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns.. respiratory tract. for example: pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis.. severe ear, nose and throat infections. for example: otitis media, mastoiditis.. urinary tract. for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only); infections associated with bladder and renal stones.. skin and soft tissue. . for e

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - ceftazidime pentahydrate, quantity: 1175 mg (equivalent: ceftazidime, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - omegapharm ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. . indications include the following.. severe infections in general. for example: septicaemia (including neonatal sepsis), bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns.. respiratory tract. for example: pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis.. severe ear, nose and throat infections. for example: otitis media, mastoiditis.. urinary tract. for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only); infections associated with bladder and renal stones.. skin and soft tissue. . for e

Malta - English - Medicines Authority

uropharm ag erfurtstrasse 64, 53125, bonn,, germany - tadalafil - film-coated tablet - tadalafil 5 mg - urologicals

Malta - English - Medicines Authority

uropharm ag erfurtstrasse 64, 53125, bonn,, germany - tadalafil - film-coated tablet - tadalafil 10 mg - urologicals